Coagulopathy: The Most Important Thing We Still Don't Know About Snakebite by Lavonas, Eric J
EDITORIAL
Coagulopathy: The Most Important Thing
We Still Don’t Know About Snakebite
Eric J. Lavonas, MD Rocky Mountain Poison and Drug Center–Denver Health, Denver, Colorado
Supervising Section Editor: Sean Henderson, MD
Submission history: Submitted August 30, 2011; Accepted August 31, 2011
Reprints available through open access at http://escholarship.org/uc/uciem_westjem
DOI: 10.5811/westjem.2011.8.6884
[West J Emerg Med. 2012;13(1):75–76.]
In this issue of Western Journal of Emergency Medicine,
Moriarty et al present a thoughtfully analyzed case series of
patients with crotaline snake envenomation.
1 They seek to
answer a common and important question: Can we deﬁne a
group of pit viper victims who are at low risk for hematologic
venom effects (ﬁbrinogen degradation and/or platelet
destruction) and spare these patients the time and expense of
serial laboratory testing? Because their institution in
Mississippi sees a large number of rattlesnake and Agkistrodon
victims, Moriarty and colleagues are well positioned to address
this question.
The answer, notwithstanding the limitations of this paper,
is no.
We know that bites inﬂicted by Agkistrodon snakes, and
particularly copperheads, are generally less severe than
rattlesnake bites. Previous studies suggest that only 10% to
20% of copperhead victims develop coagulopathy or
thrombocytopenia at any time in their clinical course, compared
with 50% or more of rattlesnake victims.
2,3 Physicians treating
copperhead victims often order relatively few blood tests; in
many cases, this can be considered standard care.
4 Similarly, it
has long been observed that early hematologic venom effects
strongly predict the late hematologic effects.
5 As a result, it
seems like patients who have completely normal early labs are
at low risk for developing coagulopathy and thrombocytopenia
later. More recent studies have refuted this observation, at least
in rattlesnake envenomation.
3 It is not clear who can forgo
testing.
These are not academic arguments. Snakebite is a blue-
collar disease. Medical bills are the leading cause of personal
bankruptcy; despite the recent housing crisis, this proportion is
actually increasing.
6 The costs of prolonged hospitalization and
serial laboratory testing, transportation, and missed work are a
real concern for our patients. In low-risk situations, practicing
medicine with no regard for cost is disrespectful and harmful.
In their very nicely conducted multivariate analysis,
Moriarity et al seem to have disproven the notion that any
patient is safe from the risk of hematologic venom effects.
Neither copperhead victim status nor low initial severity nor
any other combination of initial factors they evaluated proved
sufﬁciently sensitive to deﬁne a group of patients at low risk of
hematologic venom effects. This is particularly striking
because their observations ended at the time of hospital
discharge. Had results of postdischarge lab testing been
available for their study, Moriarity et al’s results would have
been even more convincing.
A crucial piece of this puzzle remains missing. Nearly 13
years after the ﬁrst focused evaluation of late hematologic
venom effects in the Fab-antivenom era, our understanding of
the relationship between abnormal laboratory values and the
risk of bleeding is weak and driven by anecdote.
5 To date, 4
case reports of late-onset, medically signiﬁcant bleeding have
been published.
7–10 At least 1 additional case has been litigated
to conclusion.
11 Though very worrisome, these cases must be
considered in context. Data from the National Electronic Injury
Surveillance System–All Injuries Program show that more than
8,000 patients are treated in US emergency departments for
crotaline snakebite each year.
12 In a multicenter case series of
crotaline victims, only 1 of 209 antivenom-treated patients was
reported to have delayed onset of medically signiﬁcant
bleeding.
10 None of the 42 patients in the Fab antivenom
premarketing trials had major bleeding.
13,14 Two large cohort
studies from Phoenix found no cases of delayed bleeding
among 94 patients, most of whom had coagulopathy,
thrombocytopenia, or both.
3,15 None of Moriarity et al’s 131
patients experienced bleeding, and most of the laboratory
abnormalities they evaluated posed only a minimal risk of
bleeding.
1
How many snakebite patients must we test or treat with
additional antivenom to prevent 1 case of serious bleeding?
Fortunately (for our patients), these cases are so infrequent that
the issue is nearly impossible to study. As a result, there is
currently no evidence-supported standard of care for
surveillance laboratory testing. Substantial controversy exists
Volume XIII, NO. 1 : February 2012 Western Journal of Emergency Medicine 75about what we should do with clinically occult hematologic
venom effects oncewe ﬁnd them. Moriarity et al tried to help us
out of this morass, at least for putative low-risk patients, and
found that even in this group there are no easy answers.
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